

REMARKS

In response to the Office Communication mailed October 21, 2005, Applicants have canceled claims 1-12 and added new claims 13-31. Support for the new claims can be found throughout the specification as filed, e.g., at page 3, lines 3-12; page 9, lines 18-21; page 13, lines 1-6; page 15, lines 3-7; page 50, lines 7-11; and originally filed claims 1-12. Upon entry of the amendments above, claims 13-31 will be pending. Applicants elect the invention of group I, corresponding to at least new claims 13-25 and 28-31, drawn to a method for stabilizing a protein. The election is made without traverse.

Applicants attach herewith a substitute specification and a marked-up version of the substitute specification showing all changes relative to the previously filed specification. The amendments in the substitute specification (i) clarify the translated text, (ii) insert sequence identifiers into the specification, (iii) correct amino acid position identifiers to make them consistent with the sequence listings, and (iv) insert priority information and attorney docket number. In addition, Applicants have amended Fig. 2 to correct a typographical error. No new matter has been introduced.


Applicants respectfully request examination of elected new claims 13-25 and 28-31.

No fee is believed due. Please apply any charges to deposit account 06-1050, referencing attorney docket 14875-132US1.

Respectfully submitted,

Date:

Nov. 18, 2005



Janis K. Fraser, Ph.D., J.D.

Reg. No. 34,819

Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Amendments to the Drawings:

The attached replacement sheet of drawings includes changes to Fig. 2 and replaces the original sheet on which Fig. 2 appears.

Fig. 2 on the original sheet listed the sequence "LEWIIGGNDPANG."

Fig. 2 on the replacement sheet lists the corrected sequence "LEWIGGNDPANG."


Attachments following last page of this Amendment:

Replacement Drawing Sheet (1 page)

Annotated Drawing Sheet Showing Change(s) (1 page)



FIG. 2



B HEAVY CHAIN VARIABLE REGION OF
ANTI-HUMAN TF ANTIBODY (425 bp)

